BRAF Targets in Melanoma: Biological Mechanisms, Resistance, by Ryan J. Sullivan

By Ryan J. Sullivan

​This quantity incorporates a choice of writings from the leaders within the fields of Molecular Biology and cancer learn so as to start to inform the ever-expanding tale of the newest findings, discoveries, and power of BRAF-directed objectives in cancer. fresh learn has proven that BRAF inhibitors are powerful for a quick time period, yet there's little wish that this medicines as unmarried brokers will result in sturdy gain in a majority of sufferers. between scientists and researchers who paintings in drug discovery, there's a lot of curiosity within the improvement of molecularly specified cancer causing agents. particularly, the identity of a molecular aim, the choice of molecules which successfully inhibit this goal. what's starkly various in regards to the improvement of this category of compounds, even though, is that the mechanism of motion of those brokers aren't as straight forward as used to be formerly assumed and the mechanisms of resistance that tumor cells hire to avert entire destruction are in contrast to any which were defined ahead of. those discoveries as well as usage of recent molecular biology options have ended in a sequence of hypotheses relating to which different varieties of molecules will be utilized in mixture with BRAF-inhibitors in hopes of revolutionizing the possibility of therapeutics in melanoma.

Show description

Read Online or Download BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery PDF

Similar oncology books

Prostate Cancer New Horizons in Research and Treatment

In recent times the velocity of analysis in prostate melanoma has elevated dramatically. artistic rules together with new and rising applied sciences have ended in an explosion of discovery. a lot of these advances in prostate melanoma learn presage an period of latest remedy innovations in line with an figuring out of the mobile and molecular mechanisms of sickness.

Oral Complications of Cancer and its Management

Oral difficulties are universal in melanoma sufferers. they could be a a part of the disorder itself; they could improve due to remedy; they could accompany different indicators and current as a comorbidity; and so they may first current after the unique illness itself has been cured. Oral indicators may be complicated to regard, either fighting management of doubtless life-saving remedy, and likewise without delay inflicting extra life-threatening problems.

Urologic Oncology

The research of genitourinary tumors is a space of modern swift development either within the figuring out of disorder strategies and within the improvement of latest diagnostic and healing modalities. in the course of speedy progress stages inside of any box, it really is fascinating to mirror at the present 'state of the art'. it's tricky even for specialists in reputed parts of development to tell apart precise advances from fake leads, however it is way more challenging but for these whose services lies in different parts to judge vital advances.

Neoplastic Gastrointestinal Pathology

" nearly 20 million gastrointestinal tract biopsies are played every year within the usa. whereas a lot of those are straight forward, a few are histologically refined or contain a posh differential analysis. This concise visible advisor to the total variety of neoplastic gastrointestinal specimens presents the practising pathologist or trainee with a transparent research and prognosis of either universal and almost certainly deceptive variations of illness.

Extra resources for BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery

Sample text

55. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Human Pathology. 2005;36:486–93. 56. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 2006;16:267–73. 57. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma.

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040–59. 8. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97–9. 9. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LAC, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E.

C-Kit mutants require hypoxiainducible factor 1alpha to transform melanocytes. Oncogene. 2010;29: 227–36. 62. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, Nickerson E, Auclair D, Li L, Place C, DiCara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DSB, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L.

Download PDF sample

Rated 4.74 of 5 – based on 48 votes